PPFFOOAA::LLaactcattaitoinonaannddPPllaacceennttaallTTrraannssppoorrttPPhhaarrmmaaccookkiinneettiiccStdudyyiin RnatsRats____DDuuPpoonnt.1313330099 AR22b- 155 | ~ pos le lbeadoal al, ir " TRADPSECRET Gow Budenho LE Gl Gren Study Title PFOA: Lactational and Placental Transport Pharmacokinetic Study in Rats Laboratory Project ID: DuPont-13309 T6335.)

- BACK TO MAIN 3M Environmental Laboratory Report No.

Bladder Cancer inPerfluorooctanesulfonyl Fluoride Manufacturing Workers Final Report Bruce H.

IGNACIO SERAFIN vs.

71 1 TABLE VI SOLVENT YAPJR LEVELS D tEPAHTXEHT 1* Victor WABuyAcnsunj amp casket ccotamt CHICAGO, JXLJBOIS Location of Teat Piecetone Alcohol, P.P.H.

D A N A C O R P O R A T IO N / Annual Report 2001 We are also acutely aware that many Dana shareholders have come to depend on healthy dividend payments.

Dana Corporation Completes Sale of Non-Core Businesses sales of $81 million in 2001.

Dana Corporation Page 16 of 176 these product lines, we manufacture and sell our products under a number of patents which have been obtained over a period of years and expire at various times.

Dana Corporation Page 167 of 176 Table of Contents PART IV Item 15 --Exhibits, Financial Statement Schedules, and Reports on Form 8-K 10-K Pages (a) The following documents are filed or furnished as part of this report: (1) Consolidated Financial Statements: Report of Independent Auditors Consolidated Statement of Income for each of the three years in the period ended December 31, 2003 Consolidated Balance Sheet at December 31, 2002 and 2003 Consolidated Statement of Cash Flows for each of the three years in the period ended December 31, 2003 Consolidated Statement of Shareholders' Equity for each of the three years in the period ended December 31, 2003 Notes to Consolidated Financial Statements Unaudited Quarterly Financial Information (2) Financial Statement Schedule: Valuation and Qualifying Accounts and Reserves (Schedule II) All other schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto. (3) Exhibits listed in the "Exhibit Index" Exhibits Nos. 10-A through 10-L are management contracts or compensatory plans or arrangements required to be filed pursuant to Item 15(c) of this report.

Page 5 of 8 action.

AR226-2217 PJ!"

AR226-2280 , Privileged and Confidential Attorney Work Product-Prepared in Anticipation of Litigation Summary of Meeting with DAO 'Representatives April 24. 2002 Attendees: DuPont- Rob Pinchot Debbie Mulrooney Bob Ritchey Ann Bradley WVDEP-DAQ John Benedict Chris Arrington Dave Roberts WVDEP Dee Ann Staats Chris Negley (Office of Legal Services) Dave Watkins (Division of Water - Leader of G(ST) Debbie Mulrooney provided an overview of the air modeling report that was sent to DAQ on April 19, 2002.

DuPont Engineering July 22,2002 AR226-2590 OuPontEnginoBring BarieyMillB8!.

2195 Front Street Loaan,OH43138 ONBER& State of Ohio Envirnitirtcntal PretctHun Agency Southeast District Office TELE: (740) 385-aSQI PAX; (740) 385.64BO AR226-2608 Bob Taft, Bovsrror Christopher Jones, DIrBctor July 8,2002 Mr.

AR226-3158 CONFIDENTIAL SPONSOR ElfAtochemSA Cours Michelet La Defense 10 92091 Paris-la-Defense CEDEX France TEST SUBSTANCE STUDY TITLE SKIN SENSmZATION TEST IN GUINEA-PIGS (Maximization method ofMagnusson and Kligman) STUDY DIRECTOR Xavier Manciaux STUDY COMPLETION DATE 28 August 2000 TEST FACILITY err Centre International de Toxicologie BP 563 - 27005 Evreux - France IFM Recherche wrai SM.C.W oe s M am f SIECC SOCMl :HKStir 27003 EWEUX Company Sanitized.